SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Owens RC, Jr. Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes. Pharmacotherapy 2001; 21(3): 301319.
  • 2
    Surawicz B, Knoebel SB. Long QT: good, bad or indifferent?. J Am Coll Cardiol 1984; 4(2): 398413.
  • 3
    Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350(10): 10131022.
  • 4
    Glassman AH, Bigger JT, Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158(11): 17741782.
  • 5
    Gupta A, Lawrence AT, Krishnan K, Kavinsky CJ, Trohman RG. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J 2007; 153(6): 891899.
  • 6
    De Ponti F, Poluzzi E, Montanaro N. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol 2000; 56(1): 118.
  • 7
    Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002; 287(17): 22152220.
  • 8
    FDA. FDA Drug Safety Communication: abnormal heart rhythms may be associated with use of Zofran (ondansetron). 2011; http://www.fda.gov/Drugs/DrugSafety/ucm271913.htm.
  • 9
    FDA. FDA Drug Safety Communication: abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). 2011; http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.
  • 10
    FDA. FDA Drug Safety Communication: revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. 2012; http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.
  • 11
    Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT syndrome. Prospective longitudinal study of 328 families. Circulation 1991; 84(3): 11361144.
  • 12
    Cubeddu LX. QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. Am J Ther 2003; 10(6): 452457.
  • 13
    Faber TS, Zehender M, Just H. Drug-induced torsade de pointes. Incidence, management and prevention. Drug Saf 1994; 11(6): 463476.
  • 14
    Straus SM, Sturkenboom MC, Bleumink GS, et al. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J 2005; 26(19): 20072012.
  • 15
    Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366(20): 18811890.
  • 16
    Kazmierczak J, Peregud-Pogorzelska M, Rzeuski R. QT interval prolongation and torsades de pointes due to a coadministration of ciprofloxacin and azimilide in a patient with implantable cardioverter-defibrillator. Pacing Clin Electrophysiol 2007; 30(8): 10431046.
  • 17
    Keivanidou A, Arnaoutoglou C, Krommydas A, et al. Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy. Cardiol J 2009; 16(2): 172174.
  • 18
    Letsas KP, Sideris A, Kounas SP, Efremidis M, Korantzopoulos P, Kardaras F. Drug-induced QT interval prolongation after ciprofloxacin administration in a patient receiving olanzapine. Int J Cardiol 2006; 109(2): 273274.
  • 19
    Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F. QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone. Pacing Clin Electrophysiol 2005; 28(5): 472473.
  • 20
    Boyce MJ, Baisley KJ, Warrington SJ. Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study. Br J Clin Pharmacol 2012 Mar; 73(3): 411241.
  • 21
    Burger CI, Clase CM, Gangji AS. Case report: drug interaction between tacrolimus and amiodarone with QT prolongation. Transplantation 2010; 89(9): 11661167.
  • 22
    Charbit B, Alvarez JC, Dasque E, Abe E, Demolis JL, Funck-Brentano C. Droperidol and ondansetron-induced QT interval prolongation: a clinical drug interaction study. Anesthesiology 2008; 109(2): 206212.
  • 23
    Slovacek L, Priester P, Petera J, Slanska I, Kopecky J. Tamoxifen/norfloxacin interaction leading to QT interval prolongation in a female patient with extracranial meningioma. Bratisl Lek Listy 2011; 112(6): 353354.
  • 24
    Thomas AR, Chan LN, Bauman JL, Olopade CO. Prolongation of the QT interval related to cisapride–diltiazem interaction. Pharmacotherapy 1998; 18(2): 381385.
  • 25
    Samarendra P, Kumari S, Evans SJ, Sacchi TJ, Navarro V. QT prolongation associated with azithromycin/amiodarone combination. Pacing Clin Electrophysiol 2001; 24(10): 15721574.
  • 26
    Banerjee A, Mbamalu D, Ebrahimi S, Khan AA, Chan TF. The prevalence of polypharmacy in elderly attenders to an emergency department—a problem with a need for an effective solution. Int J Emerg Med 2011; 4(1): 2224.
  • 27
    Bushardt RL, Massey EB, Simpson TW, Ariail JC, Simpson KN. Polypharmacy: misleading, but manageable. Clin Interv Aging 2008; 3(2): 383389.
  • 28
    Feudtner C, Dai D, Hexem KR, Luan X, Metjian TA. Prevalence of polypharmacy exposure among hospitalized children in the United States. Arch Pediatr Adolesc Med 2012; 166(1): 916.
  • 29
    Hohl CM, Dankoff J, Colacone A, Afilalo M. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med 2001; 38(6): 666671.
  • 30
    Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002; 287(3): 337344.
  • 31
    Vernacchio L, Kelly JP, Kaufman DW, Mitchell AA. Medication use among children <12 years of age in the United States: results from the Slone Survey. Pediatrics 2009; 124(2): 446454.
  • 32
    National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey Reason for Visit Classification and Coding Manual (updated annually). http://www.cdc.gov/nchs/ahcd.htm.
  • 33
    Budnitz DS, Shehab N, Kegler SR, Richards CL. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 2007; 147(11): 755765.
  • 34
    Curtis LH, Ostbye T, Sendersky V, et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med 2003; 114(2): 135141.
  • 35
    Allen LaPointe NM, Curtis LH, Chan KA, et al. Frequency of high-risk use of QT-prolonging medications. Pharmacoepidemiol Drug Saf 2006; 15(6): 361368.
  • 36
    Pickham D, Helfenbein E, Shinn JA, Chan G, Funk M, Drew BJ. How many patients need QT interval monitoring in critical care units? Preliminary report of the QT in Practice study. J Electrocardiol 2010; 43(6): 572576.
  • 37
    Freeman BD, Dixon DJ, Coopersmith CM, Zehnbauer BA, Buchman TG. Pharmacoepidemiology of QT-interval prolonging drug administration in critically ill patients. Pharmacoepidemiol Drug Saf 2008; 17(10): 971981.
  • 38
    Joshi AK, Sljapic T, Borghei H, Kowey PR. Case of polymorphic ventricular tachycardia in diphenhydramine poisoning. J Cardiovasc Electrophysiol 2004; 15(5): 591593.
  • 39
    Husain Z, Hussain K, Nair R, Steinman R. Diphenhydramine induced QT prolongation and torsade de pointes: an uncommon effect of a common drug. Cardiol J 2010; 17(5): 509511.
  • 40
    Sype JW, Khan IA. Prolonged QT interval with markedly abnormal ventricular repolarization in diphenhydramine overdose. Int J Cardiol 2005; 99(2): 333335.
  • 41
    Thakur AC, Aslam AK, Aslam AF, Vasavada BC, Sacchi TJ, Khan IA. QT interval prolongation in diphenhydramine toxicity. Int J Cardiol 2005; 98(2): 341343.
  • 42
    FDA. Ondansetron Label and Approval History (IV). 2011; http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020007s042,020403s020lbl.pdf.
  • 43
  • 44
    Hafermann MJ, Namdar R, Seibold GE, Page RL, 2nd. Effect of intravenous ondansetron on QT interval prolongation in patients with cardiovascular disease and additional risk factors for torsades: a prospective, observational study. Drug Healthc Patient Saf. 2011; 3: 5358.
  • 45
    Sauer AJ, Newton-Cheh C. Clinical and genetic determinants of torsade de pointes risk. Circulation 2012; 125(13): 16841694.
  • 46
    Shimizu W. The long QT syndrome: therapeutic implications of a genetic diagnosis. Cardiovasc Res 2005; 67(3): 347356.
  • 47
    Chugh SS, Reinier K, Teodorescu C, et al. Epidemiology of sudden cardiac death: clinical and research implications. Prog Cardiovasc Dis 2008; 51(3): 213228.
  • 48
    Meyer C, Stern M, Woolley W, Jeanmonod R, Jeanmonod D. How reliable are patient-completed medication reconciliation forms compared with pharmacy lists?. Am J Emerg Med 2012 Sep; 30(7): 10481054.
  • 49
    Caglar S, Henneman PL, Blank FS, Smithline HA, Henneman EA. Emergency department medication lists are not accurate. J Emerg Med 2011; 40(6): 613616.